RNA-Seq Blog Transcriptome Research & Industry News
from GenomeWeb by Monica Heger
NEW YORK (GenomeWeb) – Researchers from Massachusetts General Hospital have described a method behind two clinical cancer assays — a targeted RNA-seq fusion assay and a hotspot mutation assay — each of which the team has now used to assess more than 1,000 patients.
The method for both assays relies on anchored multiplex PCR (AMP) coupled with next-generation sequencing and was described recently in Nature Medicine.
Long Le, an assistant professor of pathology at MGH, told GenomeWeb that Enzymatics has commercialized the AMP technology. MGH had exclusively licensed the IP to startup ArcherDx, which Enzymatics subsequently purchased for $50 million last year.
